Revenue Cycle Advisory for Pathology.

Why Revenue Cycle Management Is Different for Pathology

Anatomic pathology groups and clinical laboratories process high volumes of low-dollar, high-complexity specimen claims where billing occurs without face-to-face patient contact, relying entirely on referring physician requisitions and hospital/ASC demographic feeds.

Pathology coding spans surgical pathology gross and microscopic exam tiers (88300–88309 by specimen type), special stains (88312–88314), immunohistochemistry (IHC: 88342 primary + 88341 add-on per antibody stain), FISH/molecular pathology (81105–81479), MUE unit limits, and 26/TC split billing.

• Pathology coding spans surgical pathology gross and microscopic exam tiers (88300–88309 by specimen type), special stains (88312–88314), immunohistochemistry (IHC: 88342 primary + 88341 add-on per antibody stain), FISH/molecular pathology (81105–81479), MUE unit limits, and 26/TC split billing.
• Alignment with CMS National Correct Coding Initiative (NCCI) PTP edits, MUE unit caps, and regional MAC Local Coverage Determinations (LCDs)
• Pre-bill verification of prior authorization numbers, rendering provider credentials, and site-of-service differentials
• Contractual fee-schedule modeling to catch commercial and Medicare Advantage underpayments at 835ERA posting

Prior Authorization, Medical Necessity & Denial Patterns in Pathology

Molecular diagnostic panels, genetic testing (DEX Z-Codes), and flow cytometry face strict Medicare MolDX LCDs and commercial prior authorization rules, while hospital inpatient/outpatient Date of Service (DOS) 14-Day Rule compliance governs whether technical components bill to the hospital or payer.

Pathology groups suffer heavy write-offs from truncated requisition demographics (CARC 16/31), missing referring NPIs, MUE unit denials on multiple IHC stains (failing to use 88342 x1 + 88341 xN), and MolDX/medical necessity denials.

• Front-end eligibility and benefit verification tied directly to scheduled CPT/HCPCS procedure codes and site-of-service POS indicators
• Automated tracking of payer-specific prior authorization validity windows, unit thresholds, and peer-to-peer clinical escalation timelines
• Root-cause categorization of CARC 50 (medical necessity), CARC 97 (bundling/inclusive service), CARC 197 (missing precertification), and CARC 4/16 (modifier/claim data errors)
• Contractual underpayment variance auditing against Medicare Physician Fee Schedule (MPFS), ASC payment rates, and commercial payer fee schedules

Important KPIs, Benchmarks & A/R Economics for Pathology Groups

For pathology organizations between $5M and $100M+ in net patient revenue, eliminating specialty coding friction, prior authorization write-offs, and silent payer underpayments directly improves cash velocity and operating EBITDA.

Automated front-end demographic/insurance scrubbing and HL7 requisition enrichment between LIS platforms (CoPath, NovoPath, Orchard, Epic Beaker) and lab billing engines is essential to prevent bad debt.

In-House vs. Outsourced Pathology Billing: What to Evaluate in an RCM Partner

Deciding whether to run pathology billing internally, operate a hybrid model, or outsource to a specialty RCM company requires looking past headline percentage fees. A billing vendor charging 4% that leaves 6% of net collectible revenue on the table through unappealed CARC 97/50 denials or unworked >90-day A/R costs far more than a disciplined internal or specialty-calibrated operation.

RCM Advisory Partners helps organizations benchmark their current operation before negotiating with vendors, and structures rigorous evaluation criteria when an external partner is warranted.

• Encounter-to-claim charge capture reconciliation across all pathology service locations
• Specialty CPT, HCPCS, ICD-10-CM, and modifier accuracy audit for pathology
• Prior authorization intake, medical-necessity documentation, and CARC 197/50 denial prevention
• Line-level payer allowable reconciliation and aged >90-day A/R recovery workflow review
• Verify certified coder proficiency in pathology CPT/HCPCS hierarchies, NCCI bundling edits, and Medicare LCDs
• Audit true net collection yield against contracted pathology fee schedules rather than blended gross adjustments
• Require transparent workqueue visibility on >60 and >90 day A/R and clinical appeal overturn rates

30/60/90-Day Pathology Revenue Cycle Diagnostic & Optimization Plan

Our advisory engagements translate pathology claim and remittance data into a prioritized 90-day execution roadmap:

1. 01
   Days 1–30: Specialty Claim Audit, Coding Review & Fee Schedule Reconciliation

   Audit a statistically valid sample of paid, denied, and zero-pay pathology claims across top commercial and Medicare payers; benchmark CPT/modifier distribution and identify immediate underpayment and denial recovery opportunities.

2. 02
   Days 31–60: Prior Authorization, Scrubber Edit & EHR Template Remediation

   Reconfigure front-end authorization matrices, clinical documentation templates, and clearinghouse NCCI/LCD pre-bill edits to stop preventable denials before 837 submission.

3. 03
   Days 61–90: Aged A/R Recovery, Payer Escalation & Vendor SLA Governance

   Deploy structured appeal playbooks for high-value surgical, diagnostic, or infusion claims, and establish monthly KPI scorecards holding internal leads or external billing partners accountable.